Cargando…
Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder
Antidepressant therapies, such as selective serotonin reuptake inhibitors (SSRIs), are current first-line treatments for Major Depressive Disorder. However, over 50% of treated patients show an inadequate response to initial antidepressant therapy. If the therapeutic outcomes from two antidepressant...
Autores principales: | Seo, Rubo J., MacPherson, Holly, Young, Allan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034064/ http://dx.doi.org/10.3390/ph3123522 |
Ejemplares similares
-
Meta-analysis on the efficacy and tolerability of the augmentation of
antidepressants with atypical antipsychotics in patients with major depressive
disorder
por: Wen, X.J., et al.
Publicado: (2014) -
Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
por: Yan, Tingjian, et al.
Publicado: (2020) -
Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes
por: Spielmans, Glen I., et al.
Publicado: (2013) -
PS78. Naturalistic, retrospective comparison between antidepressant therapy and atypical antipsychotic augmentation therapy for patients with major depressive disorder
por: Cho, Se Hoon, et al.
Publicado: (2016) -
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)